KLK3 and prostate carcinoma: The recent Cluster Randomized Trial of PSA Testing for Prostate Cancer found that with 40% attending the clinical visit in the screening arm for a single PSA screen in men aged 50–69 years lead to an estimated mortality reduction of 4% at ten years [9].